Dellinger J A, Taylor H L, Porges S W
Aviat Space Environ Med. 1987 Apr;58(4):333-8.
In this study, 20 human volunteers received a placebo and atropine doses of 0.5, 1.0, 2.0, and 4.0 mg X 75 kg-1 in a Latin Square double blind design, and effects were monitored for 3 h postinjection. The 2.0 mg and the 4.0 mg doses resulted in significant flight simulator performance decrements beginning at 1 h postinjection with only minimal recovery by 3 h postinjection. Electrocardiogram data were used to estimate the amplitude of respiratory sinus arrhythmia (RSA) which was more sensitive than mean heart period or mean heart period variance to the effects of atropine. These parasympathetic effects were relatively rapid in onset and peaked within the first 40-min period for the 2.0 and 4.0 mg doses. The onset of performance effects were delayed 1 h 40 min for the 2.0 mg and 1 h 00 min for the 4.0 mg treatment.
在本研究中，20名人类志愿者采用拉丁方双盲设计，接受了安慰剂以及0.5、1.0、2.0和4.0毫克×75千克-1剂量的阿托品注射，注射后3小时监测效果。2.0毫克和4.0毫克剂量导致飞行模拟器性能从注射后1小时开始显著下降，至注射后3小时仅有轻微恢复。心电图数据用于估计呼吸性窦性心律失常（RSA）的幅度，RSA对阿托品的影响比平均心动周期或平均心动周期方差更为敏感。这些副交感神经效应起效相对较快，2.0毫克和4.0毫克剂量在最初40分钟内达到峰值。2.0毫克治疗的性能效应延迟1小时40分钟出现，4.0毫克治疗延迟1小时出现。
